On November 9, 2026, the Food and Drug Administration (FDA) announced that it is requiring the holders of approved applications for every glucagon-like peptide-1 receptor agonist (GLP-1 RA) to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to their labeling. NAION is a rare condition in which reduced blood flow to the front of the optic nerve causes sudden, painless vision loss in one eye, which can be permanent. FDA describes what it found as a "potential increased risk" across the class.
The warning goes into the Warnings and Precautions section of each label. FDA's list of approved GLP-1 RAs covers semaglutide (Ozempic, Rybelsus and Wegovy), tirzepatide (Mounjaro and Zepbound), the oral small molecule orforglipron (Foundayo), and the older drugs in the class: exenatide, liraglutide, dulaglutide and lixisenatide.
What FDA reviewed
FDA traces its review to a July 2024 study in JAMA Ophthalmology by Hathaway and colleagues at Massachusetts Eye and Ear. The retrospective cohort, drawn from patients seen by neuro-ophthalmologists at one institution, found a higher NAION risk among patients prescribed semaglutide. FDA says it identified several limitations in the study but judged that the question warranted further assessment. It then weighed four kinds of evidence:
- Adverse event reports: FDA reviewed NAION reports in its Adverse Event Monitoring System, formerly FAERS, and found them hard to interpret because NAION's risk factors overlap with conditions common among people treated with these drugs.
- Clinical trials: a meta-analysis of 126 randomized controlled trials across GLP-1 RA development programs, with 134,253 participants and 288,879 person-years of exposure, found 15 probable NAION events: 10 among GLP-1 RA users, 5 on placebo and none on other glucose-lowering drugs. That is 6.4 events per 100,000 person-years with a GLP-1 RA against 3.8 with a comparator.
- Real-world data: a retrospective cohort study in FDA's Sentinel system followed adults with type 2 diabetes who started a GLP-1 RA, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024. NAION rates were 30 to 32 events per 100,000 person-years with GLP-1 RAs, 31 with SGLT-2 inhibitors and 26 with DPP-4 inhibitors.
- Published observational studies: FDA says the methodologically rigorous ones consistently found a higher NAION risk in people with type 2 diabetes starting a GLP-1 RA than in those starting a DPP-4 or SGLT-2 inhibitor.
In the Sentinel study, the increase against SGLT-2 inhibitors was not statistically significant (hazard ratio 1.19, 95% confidence interval 0.91 to 1.54). Against DPP-4 inhibitors it was (hazard ratio 1.43, 95% confidence interval 1.02 to 2.01).
FDA's review of animal data did not identify a mechanism by which GLP-1 RAs could raise NAION risk. The agency notes that NAION cases have been reported for every currently marketed GLP-1 RA, and it cites published estimates of 2.3 to 10.2 cases per 100,000 people a year among adults over 50 in the general population.
The communication also lists NAION's symptoms and its recommendations for patients and prescribers. FDA's Drug Safety Communication carries that text in full.
Europe's 2025 conclusion covered semaglutide alone
In June 2025, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION is a very rare side effect of semaglutide, a frequency it defines as up to 1 in 10,000 people. It recommended adding NAION to the product information for Ozempic, Rybelsus and Wegovy. That review was limited to semaglutide. FDA's requirement applies to the whole class, tirzepatide and orforglipron included.
What the requirement reaches
The requirement runs to application holders, so what changes is FDA-approved labeling. Compounded GLP-1 drugs and material sold for research use only have no FDA-approved label for it to change.
Several compounds in the PeptideScouter index act at the GLP-1 receptor without FDA approval. Retatrutide also activates the GIP and glucagon receptors, and mazdutide and survodutide pair the GLP-1 receptor with the glucagon receptor. None is on FDA's list of approved GLP-1 RAs, and the communication names only approved drugs.
FDA's announcement gives no date by which the revised labels must be in place.
Sources
- FDA, Drug Safety Communication: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition (November 9, 2026)
- European Medicines Agency, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 2-5 June 2025
- Hathaway JT and colleagues, Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide, JAMA Ophthalmology, 2024